

Appendix 1. Search strategy

Pubmed

#1	"Isoniazid"[Mesh] OR isoniazid [TW] OR andrazide[TW] OR antimic[TW] OR antimicina[TW] OR antimicine[TW] OR antituberkulosum trogalen[TW] OR apacizina [TW] OR armacide[TW] OR armazide[TW] OR atcotibin[TW] OR atcotibine[TW] OR azuren[TW] OR cedin[TW] OR cedin aerosol[TW] OR cemidon[TW] OR chemiazid[TW] OR chemidon[TW] OR cin vis[TW] OR cortinazine[TW] OR cotinazin[TW] OR cotinazine[TW] OR cotinizin[TW] OR cotinazine[TW] OR curazid forte[TW] OR defonin[TW] OR dianicotyl[TW] OR diazid[TW] OR dibutin[TW] OR diforin[TW] OR dinacrin[TW] OR ditubin[TW] OR dowa-isoniazid[TW] OR ebidene[TW] OR eralon[TW] OR eralone[TW] OR ertuban[TW] OR europlex[TW] OR eutizon[TW] OR eutizone[TW] OR evalon[TW] OR fimalene[TW] OR fimaline[TW] OR fsr 3[TW] OR fsr3 [TW] OR gink[TW] OR hain[TW] OR hiconyl[TW] OR hidraciber[TW] OR hidranizil[TW] OR hidrasonil[TW] OR hidrazida[TW] OR hidrazida i.n.[TW] OR hidrulte[TW] OR hycozid[TW] OR hycozide[TW] OR hydrasonil[TW] OR hydrazid[TW] OR hydrazid polfa[TW] OR hydrazide polfa[TW] OR hydrazin[TW] OR hyzyd[TW] OR ido tebin[TW] OR idrazil inh[TW] OR in 73[TW] OR inah[TW] OR INH [TI] OR inh burgthal [TW] OR inh intoxication[TW] OR inh toxicity[TW] OR inizid[TW] OR inizide[TW] OR iscotin [TW] OR iscotine[TW] OR isidrina[TW] OR isidrine[TW] OR ismazide[TW] OR isobicina[TW] OR isobicine[TW] OR isocid[TW] OR isocidene[TW] OR isocotin[TW] OR isocotine[TW] OR isokin [TW] OR isokin t [TW] OR isolyn[TW] OR isolyne[TW] OR isomazide[TW] OR isomerina[TW] OR isonerit[TW] OR isonex [TW] OR isoniac[TW] OR isoniacid[TW] OR isoniazid atlantic[TW] OR isoniazid excretion[TW] OR isoniazid intoxication[TW] OR isoniazid sensitivity[TW] OR isoniazid toxicity[TW] OR isoniazida n.t.[TW] OR isoniazide[TW] OR isoniazidine[TW] OR isoniazidum[TW] OR isoniazone[TW] OR isonicazid[TW] OR isonicazide[TW] OR isonicid[TW] OR isonicide[TW] OR isonicotan[TW] OR isonicotane[TW] OR isonicotic acid hydrazide[TW] OR isonicotil[TW] OR isonicotinic acid hydrazide[TW] OR isonicotinic acid hydrazine[TW] OR isonicotinic hydrazide[TW] OR isonicotinohydrazide[TW] OR isonicotinoylhydrazine[TW] OR isonicotinylhydrazide[TW] OR isonicotinylhydrazine[TW] OR isonide[TW] OR isonidrin[TW] OR isonidrine[TW] OR isonikazid[TW] OR isonikazide[TW] OR isonilex[TW] OR isonilyd[TW] OR isonin[TW] OR isonindon[TW] OR isonindone[TW] OR isonine[TW] OR isonirit[TW] OR isonisin[TW] OR isonisine[TW] OR isoniton[TW] OR isonitone[TW] OR isonivit[TW] OR isonizide[TW] OR isopharmide[TW] OR isotamine[TW] OR isotebe[TW] OR isotebezid[TW] OR isotebezide[TW] OR isothiavit[TW] OR isotinyl[TW] OR isozide[TW] OR isozin[TW] OR isozine[TW] OR isozone[TW] OR isozyd[TW] OR isozyde[TW] OR izoniazid[TW] OR laniazid[TW] OR medic aid isoniazid[TW] OR micosan[TW] OR micosane[TW] OR milazide[TW] OR mybasan[TW] OR mybasane[TW] OR neoteben[TW] OR neotebene[TW] OR neoxin[TW] OR neoxine[TW] OR neoxon[TW] OR neoxone[TW] OR neumandin[TW] OR nevin[TW] OR niadrin[TW] OR nicatibine[TW] OR nicazid[TW] OR nicazide[TW] OR nicetal[TW] OR nicizina[TW] OR nicodrin[TW] OR niconyl[TW] OR nicosciorin[TW] OR nicotibin[TW] OR nicotibina[TW] OR nicotibine [TW] OR nicotubin[TW] OR nicotubine[TW] OR nicozid[TW] OR nicozide [TW] OR nicozyd[TW] OR nidaton[TW] OR nidrazid[TW] OR nidrazide[TW] OR nikozid[TW] OR nikozide[TW] OR niosciorine[TW] OR niplen[TW] OR nitadon[TW] OR niteban[TW] OR nortibina[TW] OR nortibine[TW] OR nydrazid[TW] OR nydrazide [TW] OR nyscozid[TW] OR nyscozide[TW] OR pelazid[TW] OR pelazide[TW] OR percin[TW] OR phthisen[TW] OR pms isoniazid[TW] OR puran[TW] OR pycazide[TW] OR pyreazid[TW]
----	--

	OR pyreazide[TW] OR pyricidin[TW] OR pyricidine[TW] OR pyridine 4 carbohydrazide[TW] OR pyridine 4 carbonic acid hydrazide[TW] OR pyridine 4 carboxyhydrazide[TW] OR pyrizidin[TW] OR pyrizidine[TW] OR ramnanon[TW] OR raumanon[TW] OR retozide[TW] OR rhymicid[TW] OR rimicid [TW] OR rimicide[TW] OR rimifon [TW] OR rimitsid[TW] OR robisellin[TW] OR robiselline[TW] OR roxyfen miquel[TW] OR rp 5015[TW] OR ru ef tb[TW] OR sanohydrazina[TW] OR sanohydrazine[TW] OR santerazid[TW] OR santerazide[TW] OR sauterazid[TW] OR serum isoniazid[TW] OR stanozide[TW] OR supercidin[TW] OR t.b. razide[TW] OR tb phlogin [TW] OR tb phlogin heyl[TW] OR tb vis[TW] OR tebecid[TW] OR tebecide[TW] OR tebecin[TW] OR tebecine[TW] OR tebenic[TW] OR tebesium[TW] OR tebetracin[TW] OR tebetracine[TW] OR tebexin[TW] OR tebexine[TW] OR tebilon[TW] OR tebilone[TW] OR tebos[TW] OR teebaconin[TW] OR teebaconine[TW] OR tekazin[TW] OR tekazine[TW] OR thiocevit[TW] OR tibazide[TW] OR tibemid[TW] OR tibemide[TW] OR tibinide[TW] OR tibison[TW] OR tibisone[TW] OR tibitan[TW] OR tibitane[TW] OR tibivis[TW] OR tibizide[TW] OR tibusan[TW] OR tibusane[TW] OR tisin[TW] OR tisiodrazida[TW] OR tisiodrazide[TW] OR tisiotrazida[TW] OR tizide[TW] OR tubazid[TW] OR tubazide[TW] OR tubeco[TW] OR tubercid[TW] OR tuberian[TW] OR tuberiane[TW] OR tubicon[TW] OR tubicone[TW] OR tubilysin[TW] OR tubomel[TW] OR tubonil[TW] OR tubylisin[TW] OR tubylisine[TW] OR tyrid[TW] OR tyvid[TW] OR tyvide[TW] OR unicozyde[TW] OR valifol[TW] OR vazadrine[TW] OR vederon[TW] OR vederone[TW] OR vitazide[TW] OR yuhan-zid[TW] OR zinadon[TW] OR zinadone[TW] OR zonazide[TW]
#2	"Pregnant Women"[Mesh] OR "Pregnancy"[Mesh] OR "Pregnancy Complications"[Mesh] OR "Maternal Health Services"[Mesh] OR "Mothers"[Mesh] OR "Maternal Death"[Mesh] OR "Maternal-Fetal Relations"[Mesh] OR "Maternal Exposure"[Mesh] OR "Maternal Mortality"[Mesh] OR "Maternal Behavior"[Mesh] OR pregnan* [TIAB] OR Maternal*[TIAB] OR mother*[TIAB] OR child bearing [TIAB] OR perinatal [TIAB] OR Postnatal[TIAB] OR peri-natal [TIAB] OR post natal [TIAB] OR ante natal [TIAB] OR antenatal [TIAB] OR Postpartum [TIAB] OR puerperium [TIAB] OR post partum [TIAB] OR abortion* [TW] OR abortive [TW] OR "Abortion, Induced"[Mesh]
#3	"Tuberculosis"[Mesh] OR tuberculosis [TW] OR “Lupus Vulgaris ”[TIAB] OR “koch s disease ” [TW] OR tubercul*[TW] OR tuberculoma [TW] OR Silicotuberculosis [TW] OR "Tuberculosis Vaccines"[Mesh] OR "BCG Vaccine"[Mesh] OR (calmette*[TW] AND vaccin*[TW]) OR "Tuberculin Test"[Mesh] OR Tuberculin [TW] OR "Mycobacterium tuberculosis"[Mesh] OR TB [Ti]
#4	#1 AND #2 AND #3

EMBASE

#1	'isoniazid'/exp OR 'isoniazid'
#2	'pregnant woman'/exp OR 'pregnancy'/exp OR 'child bearing':ti,ab OR 'childbearing':ti,ab OR pregnant:ti,ab OR pregnancy:ti,ab OR 'breast feeding education'/exp OR 'breastfed':ti,ab OR breastfeed*:ti,ab OR (breast NEXT/2 feed*) OR 'puerperium'/exp OR 'post partum':ti,ab OR postpartum:ti,ab OR 'ante natal':ti,ab OR prenatal:ti,ab OR postnatal:ti,ab OR 'postnatal':ti,ab OR lactat*:ti,ab OR 'prenatal drug exposure'/exp OR 'maternal exposure':ti,ab
#3	'tuberculosis'/exp OR tuberculosis:ab,ti OR tuberculoses:ab,ti OR tb:ab,ti
#4	#1 AND #2 AND #3

#1	<p>mh :(isoniazid) OR tw:(isoniazid) OR tw:(andrazide) OR tw:(antimic) OR tw:(antimicina) OR tw:(antimicine) OR tw:(antituberkulosum trogalen) OR tw:(apacizina) OR tw:(armacide) OR tw:(armazide) OR tw:(atcotibin) OR tw:(atcotibine) OR tw:(azuren) OR tw:(cedin) OR tw:(cedin aerosol) OR tw:(cemidon) OR tw:(chemiazid) OR tw:(chemidon) OR tw:(cin vis) OR tw:(cortinazine) OR tw:(cotinazin) OR tw:(cotinazine) OR tw:(cotinizin) OR tw:(cotinizine) OR tw:(curazid forte) OR tw:(defonin) OR tw:(dianicotyl) OR tw:(diazid) OR tw:(dibutin) OR tw:(diforin) OR tw:(dinacrin) OR tw:(ditubin) OR tw:(dow-isoniazid) OR tw:(ebidene) OR tw:(eralon) OR tw:(eralone) OR tw:(ertuban) OR tw:(europlex) OR tw:(eutizon) OR tw:(eutizone) OR tw:(evalon) OR tw:(fimalene) OR tw:(fimaline) OR tw:(fsr 3) OR tw:(fsr3) OR tw:(gink) OR tw:(hain) OR tw:(hiconyl) OR tw:(hidraciber) OR tw:(hidranizil) OR tw:(hidrasonil) OR tw:(hidrazida) OR tw:(hidrazida i.n.) OR tw:(hidrulte) OR tw:(hycozid) OR tw:(hycozide) OR tw:(hydrasonil) OR tw:(hydrazid) OR tw:(hydrazid polfa) OR tw:(hydrazide polfa) OR tw:(hydrazin) OR tw:(hyzyd) OR tw:(ido tebin) OR tw:(idrazil inh) OR tw:(in 73) OR tw:(inah) OR ti:(INH) OR tw:(inh burgthal) OR tw:(inh intoxication) OR tw:(inh toxicity) OR tw:(inizid) OR tw:(inizide) OR tw:(iscotin) OR tw:(iscotine) OR tw:(isidrina) OR tw:(isidrine) OR tw:(ismazide) OR tw:(isobicina) OR tw:(isobicine) OR tw:(isocid) OR tw:(isocidene) OR tw:(isocotin) OR tw:(isocotine) OR tw:(isokin) OR tw:(isokin t) OR tw:(isolyn) OR tw:(isolyne) OR tw:(isomazide) OR tw:(isomerina) OR tw:(isonerit) OR tw:(isonex) OR tw:(isoniac) OR tw:(isoniacid) OR tw:(isoniazid atlantic) OR tw:(isoniazid excretion) OR tw:(isoniazid intoxication) OR tw:(isoniazid sensitivity) OR tw:(isoniazid toxicity) OR tw:(isoniazida n.t.) OR tw:(isoniazide) OR tw:(isoniazidine) OR tw:(isoniazidum) OR tw:(isoniazone) OR tw:(isonicazid) OR tw:(isonicazide) OR tw:(isonicid) OR tw:(isonicide) OR tw:(isonicotan) OR tw:(isonicotane) OR tw:(isonicotic acid hydrazide) OR tw:(isonicotil) OR tw:(isonicotinic acid hydrazide) OR tw:(isonicotinic acid hydrazine) OR tw:(isonicotinic hydrazide) OR tw:(isonicotinohydrazide) OR tw:(isonicotinoylhydrazine) OR tw:(isonicotinylhydrazide) OR tw:(isonicotinylhydrazine) OR tw:(isonide) OR tw:(isonidrin) OR tw:(isonidrine) OR tw:(isonikazid) OR tw:(isonikazide) OR tw:(isonilex) OR tw:(isonilyd) OR tw:(isonin) OR tw:(isonindon) OR tw:(isonindone) OR tw:(isonine) OR tw:(isonirit) OR tw:(isonisin) OR tw:(isonisine) OR tw:(isoniton) OR tw:(isonitone) OR tw:(isonivit) OR tw:(isonizide) OR tw:(isopharmide) OR tw:(isotamine) OR tw:(isotebe) OR tw:(isotebezid) OR tw:(isotebezide) OR tw:(isothiavit) OR tw:(isotinyl) OR tw:(isozide) OR tw:(isozin) OR tw:(isozine) OR tw:(isozone) OR tw:(isozyd) OR tw:(isozyde) OR tw:(izoniazid) OR tw:(laniazid) OR tw:(medic aid isoniazid) OR tw:(micosan) OR tw:(micosane) OR tw:(milazide) OR tw:(mybasan) OR tw:(mybasane) OR tw:(neoteben) OR tw:(neotebene) OR tw:(neoxin) OR tw:(neoxine) OR tw:(neoxon) OR tw:(neoxone) OR tw:(neumandin) OR tw:(nevin) OR tw:(niadrin) OR tw:(nicatibine) OR tw:(nicazid) OR tw:(nicazide) OR tw:(nicetal) OR tw:(nicizina) OR tw:(nicodrin) OR tw:(niconyl) OR tw:(nicosciorin) OR tw:(nicotibin) OR tw:(nicotibina) OR tw:(nicotibine) OR tw:(nicotubin) OR tw:(nicotubine) OR tw:(nicozid) OR tw:(nicozide) OR tw:(nicozyd) OR tw:(nidaton) OR tw:(nidrazid) OR tw:(nidrazide) OR tw:(nikozid) OR tw:(nikozide) OR tw:(niosciorine) OR tw:(niplen) OR tw:(nitadon) OR tw:(niteban) OR tw:(nortibina) OR tw:(nortibine) OR tw:(nydrazid) OR tw:(nydrazide) OR tw:(nyscozid) OR tw:(nyscozide) OR tw:(pelazid) OR tw:(pelazide) OR tw:(percin) OR tw:(phthisen) OR tw:(pms isoniazid) OR tw:(puran) OR tw:(pycazide) OR tw:(pyreazid) OR tw:(pyreazide) OR tw:(pyricidin) OR tw:(pyricidine) OR tw:(pyridine 4 carbohydrazide) OR tw:(pyridine 4 carbonic acid hydrazide) OR</p>
----	---

	tw:(pyridine 4 carboxyhydrazide) OR tw:(pyrizidin) OR tw:(pyrizidine) OR tw:(ramnanon) OR tw:(raumanon) OR tw:(retozide) OR tw:(rhymicid) OR tw:(rimicid) OR tw:(rimicide) OR tw:(rimifon) OR tw:(rimitsid) OR tw:(robisellin) OR tw:(robiselline) OR tw:(roxyfen miquel) OR tw:(rp 5015) OR tw:(ru ef tb) OR tw:(sanohydrazina) OR tw:(sanohydrazine) OR tw:(santerazid) OR tw:(santerazide) OR tw:(sauterazid) OR tw:(serum isoniazid) OR tw:(stanozide) OR tw:(supercidin) OR tw:(t.b. razide) OR tw:(tb phlogin) OR tw:(tb phlogin heyl) OR tw:(tb vis) OR tw:(tebecid) OR tw:(tebecide) OR tw:(tebecin) OR tw:(tebecine) OR tw:(tebenic) OR tw:(tebesium) OR tw:(tebetracin) OR tw:(tebetracine) OR tw:(tebexin) OR tw:(tebexine) OR tw:(tebilon) OR tw:(tebilone) OR tw:(tebos) OR tw:(teebaconin) OR tw:(teebaconine) OR tw:(tekazin) OR tw:(tekazine) OR tw:(thiocevit) OR tw:(tibazide) OR tw:(tibemid) OR tw:(tibemide) OR tw:(tibunide) OR tw:(tibison) OR tw:(tibisone) OR tw:(tibitan) OR tw:(tibitane) OR tw:(tibivis) OR tw:(tibizide) OR tw:(tibusan) OR tw:(tibusane) OR tw:(tisin) OR tw:(tisiodrazida) OR tw:(tisiodrazide) OR tw:(tisiotrazida) OR tw:(tizide) OR tw:(tubazid) OR tw:(tubazide) OR tw:(tubeco) OR tw:(tubercid) OR tw:(tuberian) OR tw:(tuberiane) OR tw:(tubicon) OR tw:(tubicone) OR tw:(tubilysin) OR tw:(tubomel) OR tw:(tubonil) OR tw:(tubylisin) OR tw:(tubylisine) OR tw:(tyrid) OR tw:(tyvid) OR tw:(tyvide) OR tw:(unicozyde) OR tw:(valifol) OR tw:(vazadrine) OR tw:(vederon) OR tw:(vederone) OR tw:(vitazide) OR tw:(yuhan-zid) OR tw:(zinadon) OR tw:(zinadone) OR tw:(zonazide)
#2	mh:(Pregnant Women) OR mh:(Pregnancy) OR mh:(Pregnancy Complications) OR mh:(Maternal Health Services) OR mh:(Mothers) OR mh:(Maternal Death) OR mh:(Maternal-Fetal Relations) OR mh:(Maternal Exposure) OR mh:(Maternal Mortality) OR mh:(Maternal Behavior) OR tw:(pregnan*) OR tw:(Maternal*) OR tw:(mother*) OR tw:(child bearing) OR tw:(perinatal) OR tw:(Postnatal) OR tw:(peri-natal) OR tw:(post natal) OR tw:(ante natal) OR tw:(antenatal) OR tw:(Postpartum) OR tw:(puerperium) OR tw:(post partum) OR tw:(abortion*) OR tw:(abortive) OR mh:(Abortion, Induced)
#3	mh:(Tuberculosis) OR tw:(tuberculosis) OR tw:(Lupus Vulgaris) OR tw:(koch s disease) OR tw:(tubercul*) OR tw:(tuberculoma) OR tw:(Silicotuberculosis) OR mh:(Mycobacterium tuberculosis) OR ti:(TB)
#4	#1 AND #2 AND #3

Cochran Library

#1	[mh isoniazid] OR isoniazid:ti,ab,kw OR andrazide:ti,ab,kw OR antimic:ti,ab,kw OR antimicina:ti,ab,kw OR antimicine:ti,ab,kw OR "antituberkulosum trogalen":ti,ab,kw OR apacizina:ti,ab,kw OR armacide:ti,ab,kw OR armazide:ti,ab,kw OR atcotibin:ti,ab,kw OR atcotibine:ti,ab,kw OR azuren:ti,ab,kw OR cedin:ti,ab,kw OR "cedin aerosol":ti,ab,kw OR cemidon:ti,ab,kw OR chemiazid:ti,ab,kw OR chemidon:ti,ab,kw OR "cin vis":ti,ab,kw OR cortinazine:ti,ab,kw OR cotinazin:ti,ab,kw OR cotinazine:ti,ab,kw OR cotinizin:ti,ab,kw OR cotinizine:ti,ab,kw OR "curazid forte":ti,ab,kw OR defonin:ti,ab,kw OR dianicotyl:ti,ab,kw OR diazid:ti,ab,kw OR dibutin:ti,ab,kw OR diforin:ti,ab,kw OR dinacrin:ti,ab,kw OR ditubin:ti,ab,kw OR dow-isoniazid:ti,ab,kw OR ebidene:ti,ab,kw OR eralon:ti,ab,kw OR eralone:ti,ab,kw OR ertuban:ti,ab,kw OR europlex:ti,ab,kw OR eutizon:ti,ab,kw OR eutizone:ti,ab,kw OR evalon:ti,ab,kw OR fimalene:ti,ab,kw OR fimaline:ti,ab,kw OR "fsr 3":ti,ab,kw OR fsr3:ti,ab,kw OR gink:ti,ab,kw OR hain:ti,ab,kw OR hiconyl:ti,ab,kw OR hidraciber:ti,ab,kw OR hidranizil:ti,ab,kw OR hidrasonil:ti,ab,kw OR hidrazida:ti,ab,kw OR hidrazida i.n.:ti,ab,kw OR hidrulte:ti,ab,kw OR hycozid:ti,ab,kw OR hycozide:ti,ab,kw OR hydrasonil:ti,ab,kw OR hydrazid:ti,ab,kw OR "hydrazid polfa":ti,ab,kw OR "hydrazide polfa":ti,ab,kw OR
----	---

hydrazin:ti,ab,kw OR hyzyd:ti,ab,kw OR "ido tebin":ti,ab,kw OR "idrazil inh":ti,ab,kw OR "in 73":ti,ab,kw OR inah:ti,ab,kw
 OR INH:ti OR "inh burgthal":ti,ab,kw OR "inh intoxication":ti,ab,kw OR "inh toxicity":ti,ab,kw OR inizid:ti,ab,kw OR
 inizide:ti,ab,kw OR iscotin:ti,ab,kw OR iscotine:ti,ab,kw OR isidrina:ti,ab,kw OR isidrine:ti,ab,kw OR ismazide:ti,ab,kw OR
 isobicina:ti,ab,kw OR isobicine:ti,ab,kw OR isocid:ti,ab,kw OR isocidene:ti,ab,kw OR isocotin:ti,ab,kw OR isocotine:ti,ab,kw
 OR isokin:ti,ab,kw OR "isokin t":ti,ab,kw OR isolyn:ti,ab,kw OR isolyne:ti,ab,kw OR isomazide:ti,ab,kw OR
 isomerina:ti,ab,kw OR isonerit:ti,ab,kw OR isonex:ti,ab,kw OR isoniac:ti,ab,kw OR isoniacid:ti,ab,kw OR "isoniazid
 atlantic":ti,ab,kw OR "isoniazid excretion":ti,ab,kw OR "isoniazid intoxication":ti,ab,kw OR "isoniazid sensitivity":ti,ab,kw OR
 "isoniazid toxicity":ti,ab,kw OR "isoniazida n.t.":ti,ab,kw OR isoniazide:ti,ab,kw OR isoniazidine:ti,ab,kw OR
 isoniazidum:ti,ab,kw OR isoniazone:ti,ab,kw OR isonicazid:ti,ab,kw OR isonicazide:ti,ab,kw OR isonicid:ti,ab,kw OR
 isonicide:ti,ab,kw OR isonicotan:ti,ab,kw OR isonicotane:ti,ab,kw OR "isonicotinic acid hydrazide":ti,ab,kw OR isonicotil:ti,ab,kw
 OR "isonicotinic acid hydrazide":ti,ab,kw OR "isonicotinic acid hydrazine":ti,ab,kw OR "isonicotinic hydrazide":ti,ab,kw OR
 isonicotinohydrazide:ti,ab,kw OR isonicotinoylhydrazine:ti,ab,kw OR isonicotinylhydrazide:ti,ab,kw OR
 isonicotinylhydrazine:ti,ab,kw OR isonide:ti,ab,kw OR isonidrin:ti,ab,kw OR isonidrine:ti,ab,kw OR isonikazid:ti,ab,kw OR
 isonikazide:ti,ab,kw OR isonilex:ti,ab,kw OR isonilyd:ti,ab,kw OR isonin:ti,ab,kw OR isonindon:ti,ab,kw OR
 isonindone:ti,ab,kw OR isonine:ti,ab,kw OR isonirit:ti,ab,kw OR isonisin:ti,ab,kw OR isonisine:ti,ab,kw OR isoniton:ti,ab,kw
 OR isonitone:ti,ab,kw OR isonivit:ti,ab,kw OR isonizide:ti,ab,kw OR isopharmide:ti,ab,kw OR isotamine:ti,ab,kw OR
 isotebe:ti,ab,kw OR isotebezid:ti,ab,kw OR isotebezide:ti,ab,kw OR isothiavit:ti,ab,kw OR isotinyl:ti,ab,kw OR isozide:ti,ab,kw
 OR isozin:ti,ab,kw OR isozine:ti,ab,kw OR isozone:ti,ab,kw OR isozyd:ti,ab,kw OR isozyde:ti,ab,kw OR izoniazid:ti,ab,kw OR
 laniazid:ti,ab,kw OR "medic aid isoniazid":ti,ab,kw OR micosan:ti,ab,kw OR micosane:ti,ab,kw OR milazide:ti,ab,kw OR
 mybasan:ti,ab,kw OR mybasane:ti,ab,kw OR neoteben:ti,ab,kw OR neotebene:ti,ab,kw OR neoxin:ti,ab,kw OR neoxine:ti,ab,kw
 OR neoxon:ti,ab,kw OR neoxone:ti,ab,kw OR neumandin:ti,ab,kw OR nevin:ti,ab,kw OR niadrin:ti,ab,kw OR
 nicatibine:ti,ab,kw OR nicazid:ti,ab,kw OR nicazide:ti,ab,kw OR nicetal:ti,ab,kw OR nicizina:ti,ab,kw OR nicodrin:ti,ab,kw OR
 niconyl:ti,ab,kw OR nicosciorin:ti,ab,kw OR nicotibin:ti,ab,kw OR nicotibina:ti,ab,kw OR nicotibine:ti,ab,kw OR
 nicotubin:ti,ab,kw OR nicotubine:ti,ab,kw OR nicozid:ti,ab,kw OR nicozide:ti,ab,kw OR nicozyd:ti,ab,kw OR nidaton:ti,ab,kw
 OR nidrazid:ti,ab,kw OR nidrazide:ti,ab,kw OR nikozid:ti,ab,kw OR nikozide:ti,ab,kw OR niosciorine:ti,ab,kw OR
 niplen:ti,ab,kw OR nitadon:ti,ab,kw OR niteban:ti,ab,kw OR nortibina:ti,ab,kw OR nortibine:ti,ab,kw OR nydrazid:ti,ab,kw OR
 nydrazide:ti,ab,kw OR nyscozid:ti,ab,kw OR nyscozide:ti,ab,kw OR pelazid:ti,ab,kw OR pelazide:ti,ab,kw OR percin:ti,ab,kw
 OR phthisen:ti,ab,kw OR "pms isoniazid":ti,ab,kw OR puran:ti,ab,kw OR pycazide:ti,ab,kw OR pyreazid:ti,ab,kw OR
 pyreazide:ti,ab,kw OR pyricidin:ti,ab,kw OR pyricidine:ti,ab,kw OR "pyridine 4 carbohydrazide":ti,ab,kw OR "pyridine 4
 carbonic acid hydrazide":ti,ab,kw OR "pyridine 4 carboxyhydrazide":ti,ab,kw OR pyrizidin:ti,ab,kw OR pyrizidine:ti,ab,kw OR
 ramnanon:ti,ab,kw OR raumanon:ti,ab,kw OR retozide:ti,ab,kw OR rhymicid:ti,ab,kw OR rimicid:ti,ab,kw OR rimicide:ti,ab,kw
 OR rimifon:ti,ab,kw OR rimitsid:ti,ab,kw OR robisellin:ti,ab,kw OR robiselline:ti,ab,kw OR "roxyfen miquel":ti,ab,kw OR "rp
 5015":ti,ab,kw OR "ru ef tb":ti,ab,kw OR sanohydrazina:ti,ab,kw OR sanohydrazine:ti,ab,kw OR santerazid:ti,ab,kw OR
 santerazide:ti,ab,kw OR sauterazid:ti,ab,kw OR "serum isoniazid":ti,ab,kw OR stanozide:ti,ab,kw OR supercidin:ti,ab,kw OR
 "t.b. razide":ti,ab,kw OR "tb phlogin":ti,ab,kw OR "tb phlogin heyl":ti,ab,kw OR "tb vis":ti,ab,kw OR tebecid:ti,ab,kw OR
 tebecide:ti,ab,kw OR tebecin:ti,ab,kw OR tebecine:ti,ab,kw OR tebenic:ti,ab,kw OR tebesium:ti,ab,kw OR tebetracin:ti,ab,kw

	OR tebetracine:ti,ab,kw OR tebexin:ti,ab,kw OR tebexine:ti,ab,kw OR tebilon:ti,ab,kw OR tebilone:ti,ab,kw OR tebos:ti,ab,kw OR teebaconin:ti,ab,kw OR teebaconine:ti,ab,kw OR tekazin:ti,ab,kw OR tekazine:ti,ab,kw OR thiocevit:ti,ab,kw OR tibazide:ti,ab,kw OR tibemid:ti,ab,kw OR tibemide:ti,ab,kw OR tibinide:ti,ab,kw OR tibison:ti,ab,kw OR tibisone:ti,ab,kw OR tibitan:ti,ab,kw OR tibitane:ti,ab,kw OR tibivis:ti,ab,kw OR tibizide:ti,ab,kw OR tibusan:ti,ab,kw OR tibusane:ti,ab,kw OR tisin:ti,ab,kw OR tisiodrazida:ti,ab,kw OR tisiodrazide:ti,ab,kw OR tisiotrazida:ti,ab,kw OR tizide:ti,ab,kw OR tubazid:ti,ab,kw OR tubazide:ti,ab,kw OR tubeco:ti,ab,kw OR tubercid:ti,ab,kw OR tuberian:ti,ab,kw OR tuberiane:ti,ab,kw OR tubicon:ti,ab,kw OR tubicone:ti,ab,kw OR tubilysin:ti,ab,kw OR tubomel:ti,ab,kw OR tubonil:ti,ab,kw OR tubylisin:ti,ab,kw OR tubylisine:ti,ab,kw OR tyrid:ti,ab,kw OR tyvid:ti,ab,kw OR tyvide:ti,ab,kw OR unicozyde:ti,ab,kw OR valifol:ti,ab,kw OR vazadrine:ti,ab,kw OR vederon:ti,ab,kw OR vederone:ti,ab,kw OR vitazide:ti,ab,kw OR yuhan-zid:ti,ab,kw OR zinadon:ti,ab,kw OR zinadone:ti,ab,kw OR zonazide:ti,ab,kw
#2	[mh "Pregnant Women"] OR [mh Pregnancy] OR [mh "Pregnancy Complications"] OR [mh "Maternal Health Services"] OR [mh Mothers] OR [mh "Maternal Death"] OR [mh "Maternal-Fetal Relations"] OR [mh "Maternal Exposure"] OR [mh "Maternal Mortality"] OR [mh "Maternal Behavior"] OR (pregnan*):ti,ab,kw OR (Maternal*):ti,ab,kw OR (mother*):ti,ab,kw OR ("child bearing"):ti,ab,kw OR (perinatal):ti,ab,kw OR (Postnatal):ti,ab,kw OR (peri-natal):ti,ab,kw OR ("post natal"):ti,ab,kw OR ("ante natal"):ti,ab,kw OR (antenatal):ti,ab,kw OR (Postpartum):ti,ab,kw OR (puerperium):ti,ab,kw OR ("post partum"):ti,ab,kw OR (abortion*):ti,ab,kw OR (abortive):ti,ab,kw OR [mh "Abortion, Induced"]
#3	[mh Tuberculosis] OR (tuberculosis):ti,ab,kw OR ("Lupus Vulgaris"):ti,ab,kw OR ("koch s disease"):ti,ab,kw OR (tubercul*):ti,ab,kw OR (tuberculoma):ti,ab,kw OR (Silicotuberculosis):ti,ab,kw OR [mh "Mycobacterium tuberculosis"] OR (TB):ti
#4	#1 AND #2 AND #3

Appendix 2. Supplementary tables

Table S1. Risk of bias assessment-Maternal outcomes

Table S1.1-randomized trial (RoB2)

	Randomization process	Deviations from intended interventions	Missing outcome data	Measurement of the outcome	Selection of the reported result	Overall
Gupta et al, 2019	Low risk	Low risk	Some concern	Low risk	Low risk	Some concern

Table S1.2-Non-randomized studies

	Confounding	Selection	Classification	Deviation	Missing outcome data	Measurement of the outcome	Selection of the reporting result	Overall
Chang et al, 2013*	-	Low risk	Low risk	-	Moderate risk	Moderate risk	-	Moderate risk
Frank et al 1989*	-	Moderate risk	Moderate risk	-	Serious risk	Serious risk	-	Serious risk
Kalk et al, 2018	Serious risk	Risk	Moderate risk	Low risk	No information	Moderate risk for maternal deaths and serious risk for hepatotoxicity	Low risk	Serious risk
Moro et al, 2018	Serious risk	Serious risk	Serious risk	Low risk	Moderate risk	Low risk for death and serious risk for other adverse events	Low risk	Serious risk
Salazar-Nicole et al, 2019	Serious risk	Low risk	Low risk	Low risk	Low risk	Low risk	Moderate risk	Serious risk
Taylor et al, 2013	Serious risk	Serious risk	Moderate risk	Low risk	Moderate risk	Low risk	Moderate risk	Serious risk
Tiam et al, 2014*	-	Low risk	Low risk	-	Moderate risk	Moderate risk	-	Moderate risk

*No control group as defined in the review. - indicates domains that were not assessed due to lack of a control group.

Table S2. Risk of bias assessment-Pregnancy outcomes*Table S2.1-randomized trial (RoB2)*

	Randomization process	Deviations from intended interventions	Missing outcome data	Measurement of the outcome	Selection of the reported result	Overall
Gupta et al, 2019	Low risk	Low risk	Some concern	Low risk	Low risk	Some concern

Table S2.2-Non-randomized studies

	Confounding	Selection	Classification	Deviation	Missing outcome data	Measurement of the outcome	Selection of the reporting result	Overall
Kalk et al, 2018	Serious risk	Low risk	Moderate risk	Low risk	Serious risk	Moderate risk	Moderate risk	Serious risk
Moro et al, 2018	Serious risk	Serious risk	Serious risk	Low risk	Moderate risk	Serious risk	Low risk	Serious risk
Msandiwa et al, 2009*	-	Serous risk	Moderate risk	-	Moderate risk	Low risk	-	Serious risk
Salazar-Nicole et al, 2019	Serious risk	Low risk	Low risk	Low risk	Low risk	Moderate risk	Serious risk	Serious risk
Taylor et al, 2013	Serious risk	Serious risk	Moderate risk	Low risk	Moderate risk	Low risk	Moderate risk	Serious risk

*No control group as defined in the review. - indicates domains that were not assessed due to lack of a control group.

In the RCT by Gupta et al, 15.9% (76/477) in immediate IPT arm and 17.3% (83/479) in deferred IPT arm did not complete study mostly due to withdrawal or loss to follow-up. Time-to-last clinic visit was balanced between the two arms and hence risk of bias due to missing outcome data was considered of “some concern” rather than “serious”. The risk of bias was considered low in the other domains. Of the four NRS with a control group that reported pregnancy outcomes, all were considered at serious risk of bias due to inadequate control of confounding factors. Furthermore, two of them included only women who became pregnant after starting IPT during the trial and therefore they were considered at serious risk of selection bias. The study by Moro et al was considered at serious risk of bias in classification of interventions and outcomes, since that was estimated based on case reporting forms filled out inconsistently by study site staff. In the study by Kalk et al, pregnancy outcomes were missing in 35 % of women in the IPT group and 36% in those not put on IPT and therefore considered at serious risk of bias. In the study by Salazar-Austin et al, multiple composite outcomes were reported and there was no indication that they were defined *a priori*; hence the study was considered at serious risk of bias in selection of the reported results.

Table S3. Hepatotoxicity in included studies

	Population	Definition	Measurement	IPT	Control	Effect (95%CI)
Chang et al, 2013	Postpartum Women (>2 months after delivery) No HIV status reported.	ALT>3 times upper limit with symptoms or > 5 times upper limit normal regardless of symptoms	If clinically indicated.	1.9%* among postpartum women aged 18 to 35.	NA	NA
Frank et al, 1989	Women enrolled in prenatal IPT program	Symptom of hepatitis with AST>4 times upper limit with no evidence to suggest other etiologies	No routine LFT for asymptomatic women. LFT only for those with suggestive symptoms. Follow-up was every 3 months	15-34years:3/3324 (0.09%) 3/1171 py (2.6/1000p-y) 35-44 years: 2/237 (0.8%) 2/88 py (22.7/1000p-y)	NA	NA
Gupta et al, 2019	HIV-positive pregnant women	≥ grade 3 liver enzyme elevation (LEE); ≥ grade 2 total bilirubin and ≥ grade 2 ALT; or ≥ grade 2 ALT with symptomatic clinical hepatitis	LFT performed at every visit	18/477 (3.8%)#	Placebo 11/479 (2.3%)#	RR 1.64 (0.78-3.44)
Kalk et al, 2018	HIV-positive pregnant women on or initiating ART	ALT>=5x ULN	If clinically indicated	30/10715 (0.3%)	No treatment 114/41227 (0.3%)	RR 1.01 (0.68-1.51)
Moro et al, 2018	Women who became pregnant during two parents trials. (All but one are HIV-negative)	1)AST >= 5x ULN, regardless of signs or symptoms of hepatitis 2)AST >= 3x ULN, in the presence of signs or symptoms of hepatitis	If clinically indicated or presence of baseline abnormality	1/56 (1.8%)	3HP 0/31	RR 1.68 (0.07-40.1)*
Tiam et al, 2014	HIV-positive pregnant women.	Not defined	If clinically indicated or presence of baseline abnormality	0/124 (0%)	NA	NA
Taylor et al, 2013	HIV-positive pregnant women who became pregnant during a parent trial.	Elevation of liver enzymes to >5 times the upper limit of normal.	2 weeks after enrollment and if clinically indicated	0/103 (0%)	NA	NA

*228 post-partum women were included in the study. No data on number of post-partum women aged 18-35 years old.

The analysis was restricted to events occurred until 3 months post-partum. Some were still on IPT and were censored.

Table S4. Grade 3 or 4 adverse events due to treatment in included studies

	Population	Definition	Measurement	IPT	Control	Effect
Gupta et al, 2019	HIV-positive pregnant women	Treatment related Grade 3 or 4 as per DAIDS table	Visits occurred every 4 weeks during pregnancy, at labor and delivery, and every 4 weeks after delivery through 48 weeks	34/477 (7.1%)	Placebo: 22/479 (4.6%)	RR 1.55 (0.92-2.61)
Moro et al, 2018	Women who became pregnant during two parents trials. (All but one are HIV-negative)	All events were graded using the U.S. National Cancer Institute Common Toxicity Criteria, version 2.0.	Monthly clinical monitoring	1/56 (1.8%)	3HP: 0/31 (0%)	RR 1.68 (0.07-40.1)
Tiam et al, 2014	HIV-positive pregnant women.	Patients were assessed for side effects and toxicities related to INH, including gastrointestinal and central nervous system side effects, and peripheral neuropathy. None reported clinical side effects.	Monthly clinical monitoring.	0/124 (0%)	NA	NA

Table S5 Maternal deaths in included studies

	Population	IPT	Control	Effect (95%CI)
Gupta et al, 2019	HIV-positive pregnant women	1/477 (0.2%)	Placebo: 3/479 (0.6%)	RR: 0.33 (0.03 - 3.21)
Kalk et al, 2018	HIV-positive pregnant women on or initiating ART	INH: 18/10715 (0.2%)	No treatment: 103/41227 (0.3%)	RR: 0.67 (0.41-1.11)
Moro et al, 2018	Women who became pregnant during the two parent trials. (All but one HIV-negative)	INH: 0/56	3HP: 0/31	NA
Salazar-Austin, et al, 2019	HIV-positive pregnant women	INH: 0/71	No INH exposure: 2/84 (2%)	RR: 0.24 (95%CI: 0.01-4.84)
Tiam et al, 2014	HIV-positive pregnant women.	INH: 2/124 (1.6%)	NA	NA
Taylor et al, 2013	HIV-positive pregnant women who became pregnant during a parent trial.	INH: 0/103	No INH exposure: 0/93	NA

Table S6. Composite adverse pregnancy outcomes in included studies

	Population	Composite outcomes	IPT	Control	Effect (95%CI)
Gupta et al, 2019	HIV-positive pregnant women	Low birth weight, preterm delivery spontaneous abortion, stillbirth, or major congenital anomaly	106/449 (23.6%)	78/460 (16.0%)	OR* 1.51 (1.09-2.10)
Kalk et al, 2018	HIV-positive pregnant women on or initiating ART	Low birth weight, preterm delivery, termination of pregnancy, still birth, or neonatal death	1093/6922 (16.9%)	4687/26363 (19.5%)	OR 0.87 (0.81-0.93), unadjusted.
Taylor et al, 2013	HIV-positive pregnant women who became pregnant during a parent trial.	Low birth weight, preterm delivery, spontaneous abortion, stillbirth, neonatal mortality (death of term infant within 28 days of delivery), or any noted congenital anomaly	32/103 (31.1%)	40/93 (43.0%)	OR 0.6 (0.3-1.1) Adjusted by maternal age, BMI, CD4, and ART
Salazar-Austin et al, 2019	HIV-positive pregnant women	Low birth weight, preterm delivery, spontaneous abortion, stillbirth, and congenital anomaly	11/69 (15.9%)	23/82 (28.90%)	OR 0.36 (0.14-0.88) Adjusted by maternal age, CD4, viral load, PMTCT regimen, BMI, anemia.

*Mantel-Haenszel OR stratified by gestational age

Table S7. Still birth, spontaneous abortion, or neonatal death in included studies.

	Population	IPT	Control	Effect measure (95%CI)
Gupta et al, 2019	HIV-positive pregnant women	21/459 (4.6%)	Placebo 14/466 (3.0%)	RR 1.52 (0.78-2.96)
Kalk et al, 2018	HIV-positive pregnant women on or initiating ART	308/6922 (4.4%)	No treatment 1568/26363 (5.9%)	RR 0.75 (0.66-0.84)
Moro et al, 2018	Women who became pregnant during two parents trials. (All but one are HIV-negative)	8/56 (14%)	No drug exposure: 5/39 (13%) 3HP:4/31(13%)	VS no exposure: RR 1.11 (0.39-3.15) VS 3HP RR 1.11 (0.36-3.38)
Msandiwa et al, 2009	HIV-positive women who became pregnant under the parent trial	3/34* (9%)	N/A	NA
Salazar-Austin et al, 2019	HIV-positive pregnant women	2/69 (2.9%)	No treatment 1/82 (1%)	RR 2.38 (0.22-25.7)

*8/34 participants were exposed to rifamycin-containing regimens and were switched to INH alone or discontinued. Data on outcomes disaggregated by regimens were not available.

Table S8. Prematurity in included studies.

	Population	Definition	IPT	control	Effect measure (95%CI)
Gupta et al, 2019	HIV-positive pregnant women	<37 weeks using the Ballard examination, when available, or obstetrical estimate)	48/442 (10.9%)	Placebo 40/458 (8.7%)	RR 1.24 (0.83-1.85)
Kalk et al, 2018	HIV-positive pregnant women on or initiating ART	<37 weeks	929/6922 (13.4%)	No treatment 3969/26363 (15.1%)	RR 0.89 (0.83-0.95)
Msandiwa et al, 2009	HIV-positive women who became pregnant under the parent trial	No information available	1/34 (2.9%)	N/A	NA
Salazar-Austin et al, 2019	HIV-positive pregnant women	Any <37 weeks	7/69 (10.1%)	No treatment 18/82 (22.0%)	RR 0.46 (0.21-1.04)

Table S9. Low birth weight in included studies

	Population	Definition	INH	control	Effect
Gupta et al, 2019	HIV-positive pregnant women	<2500g	62/430 (14.4%)	Placebo 46/446 (10.3%)	RR 1.40 (0.98-2.00)
Kalk et al, 2018	HIV-positive women who became pregnant under the parent trial	<2500g	1029/6922 (14.9%)	No treatment 4410/26363(16.7%)	RR 0.89 (0.83-0.95)
Salazar-Austin et al, 2019	HIV-positive pregnant women	<2500g	6/69 (8.7%)	No treatment 10/82 (12.2%)	RR 0.71(0.27-1.86)

Table S10. Congenital anomaly in included studies

	Population	Definition	IPT	Control	Effect (95%CI)
Gupta et al, 2019	HIV-positive pregnant women	According to the Metropolitan Atlanta Congenital Defects Program of the US Centers for Disease Control and Prevention	10/440 (2.3%)	Placebo 6/458 (1.3%)	RR 1.74 (0.64-4.73)
Moro et al, 2018	Women who became pregnant during two parents trials. (All but one are HIV-negative)	Any report of congenital anomaly defined by the local investigator.	2/41 (5%)	No exposure: 1/32 (3%) 3HP: 0/20 (0%)	RR 1.56 (0.15-16.5) RR 2.5 (0.13-49.8)
Salazar-Austin et al, 2019	HIV-positive pregnant women	Not defined	1/69 (1.4%)	No treatment 2/82 (2.4%)	RR 0.59 (0.06-6.41)